A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

Cencora COR is slated to report first-quarter fiscal 2025 results on Feb. 05, before market open. In the last reported ...

Medical experts have long warned about alcohol's risks, and now the drinks industry is embracing sobriety, investing in ...

More and more people are taking weight loss injectables like Wegovy and Mounjaro — and pharmacy experts are worried that not ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Research tells us that eating enough protein and staying physically active can be helpful in reducing the amount of non-fat ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

The anti-amyloid antibody has been included in the Japan National Health Insurance (NHI) Drug Price List at just under JPY 3 million (around $20,500) per patient per year, whereas in the US its ...